| 000 | 01874 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518082703.0 | ||
| 264 | 0 | _c20200828 | |
| 008 | 202008s 0 0 eng d | ||
| 022 | _a1365-2036 | ||
| 024 | 7 |
_a10.1111/apt.15637 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aShah, Eric D | |
| 245 | 0 | 0 |
_aSystematic review: hepatosplenic T-cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _c03 2020 |
||
| 300 |
_a527-533 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Systematic Review | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAdverse Drug Reaction Reporting Systems _xstatistics & numerical data |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aBiological Products _xtherapeutic use |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInflammatory Bowel Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aLiver Neoplasms _xchemically induced |
| 650 | 0 | 4 |
_aLymphoma, T-Cell _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSplenic Neoplasms _xchemically induced |
| 650 | 0 | 4 |
_aUnited States _xepidemiology |
| 650 | 0 | 4 | _aUnited States Food and Drug Administration |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aCoburn, Elliot S | |
| 700 | 1 | _aNayyar, Anil | |
| 700 | 1 | _aLee, Kerry Jo | |
| 700 | 1 | _aKoliani-Pace, Jenna L | |
| 700 | 1 | _aSiegel, Corey A | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 51 _gno. 5 _gp. 527-533 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/apt.15637 _zAvailable from publisher's website |
| 999 |
_c30568885 _d30568885 |
||